Chitosan, Intrabony Defect, Nano-hydroxyapatite Hydrogel
Conditions
Brief summary
The aim of this study was to evaluate the clinical effect of Chitosan with nano-hydroxyapatite hydrogel in the treatment of periodontal intrabony defects.
Detailed description
Periodontitis is a chronic inflammation of the periodontium that extends beyond the gingiva and involves the destruction of the connective tissue attachment of the teeth. Treatment modalities of periodontitis includes local drug delivery such as chitosan which is a derivative of the exoskeleton of many arthropods including prawns, lobsters and crabs. Chitosan has been used in guided bone regeneration, hemostasis of surgical wounds, and coating of dental implants, in reconstruction of temporomandibular joint disc and guided periodontal tissue regeneration. Moreover, chitosan has been used for preventing demineralization. HA also called hydroxylapatite, is a naturally occurring mineral form of calcium apatite with the formula Ca5(PO4)3(OH). The OH- ion can be replaced by fluoride, and carbonate, producing fluorapatite or chlorapatite. It crystallizes in the hexagonal crystal system.
Interventions
OTHERNano-HAP/Chitosan hydrogel
The periodontal pockets more than or equal 3-5mm were isolated. Chitosan and nano-HAP hydrogel were prepared in the same steps that were mentioned in the methodology and then the prepared gel was applied to the test site of patients with the deepest probing pocket measurement once per week for 3 weeks. Periodontal dressing (Coe-pack) was to secure the hydrogel in place.
Sponsors
October 6 University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Age from 25 to 55 years. * Both sexes. * Patients with stage II to III periodontitis with probing pocket depths ≥ 5 mm and radiographic evidence showing infrabony defect.
Exclusion criteria
* Patients received periodontal or antibiotic therapy within the previous 6 months preceding the study. * Smokers. * Pregnant and lactating females. * Patients on medications known to affect bone turnover or with known side effects to chitosan, nano-hydroxyapatite, and collagen membrane.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gingival index | 6 months after treatment | Gingival index (GI) used for the assessment of prevalence and severity of gingivitis. A score from 0 to 3 is given to each area of the tooth.0.1-1.0 = mild inflammation; 1.1-2.0 = moderate inflammation from, and 2.1-3.0 signifies severe inflammation. It was evaluated for every patient included in the study, 3 and at 6 months after treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plaque index | 6 months after treatment | Plaque index (PI) was used to assess oral hygiene where 0 = no plaque. 1 = separate flecks of plaque at the cervical margin of the tooth. 2 = a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth. It was evaluated for every patient included in the study, 3 and at 6 months after treatment. |
| Clinical attachment level | 6 months after treatment | Clinical attachment level (CAL) was evaluated for every patient included in the study, 3 and at 6 months after treatment. |
| Periodontal probing depth | 6 months after treatment | Periodontal probing depth (PD) (referred to as pocket depth if periodontal disease is present) is the distance from the gingival margin to the apical portion of the gingival sulcus. Probing depths in healthy gingival sulci normally range from 1 to 3 mm. It was evaluated for every patient included in the study, 3 and at 6 months after treatment. |
| Acrylic stent for pocket assessment | 6 months after treatment | Acrylic stent for pocket assessment was evaluated for every patient included in the study, 3 and at 6 months after treatment. |
Countries
Egypt
Outcome results
None listed